Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

被引：5
|
作者：
Awan, F. T. [1 ]
Osman, S. [2 ]
Kochuparambil, S. T. [1 ]
Gibson, L. [2 ]
Remick, S. C. [2 ]
Abraham, J. [2 ]
Craig, M. [2 ]
Jillella, A. [1 ]
Hamadani, M. [2 ]
机构：
[1] Med Coll Georgia, Dept Internal Med, Div Hematol Oncol, Augusta, GA 30912 USA
[2] W Virginia Univ, MBRCC, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷 / 01期
关键词：
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; AUTOTRANSPLANTATION; CHEMOTHERAPY; TRIAL;
D O I：
10.1038/bmt.2011.18
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：146 / 148
页数：3
相关论文
共 50 条
  • [1] Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation
    F T Awan
    S Osman
    S T Kochuparambil
    L Gibson
    S C Remick
    J Abraham
    M Craig
    A Jillella
    M Hamadani
    Bone Marrow Transplantation, 2012, 47 : 146 - 148
  • [2] Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation - A Multicenter Analysis
    Awan, Farruku
    Osman, Salman
    Kochuparambil, Samith Thomas
    Remick, Scot
    Abraham, Jame
    Craig, Michael
    Jillella, Anand P.
    Hamadani, Sayed Mehdi
    BLOOD, 2010, 116 (21) : 580 - 580
  • [3] Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
    Kumar, Shaji
    Giralt, Sergio
    Stadtmauer, Edward A.
    Harousseau, Jean L.
    Palumbo, Antonio
    Bensinger, William
    Comenzo, Raymond L.
    Lentzsch, Suzanne
    Munshi, Nikhil
    Niesvizky, Ruben
    Miguel, Jesus San
    Ludwig, Heinz
    Bergsagel, Leif
    Blade, Joan
    Lonial, Sagar
    Anderson, Kenneth C.
    Tosi, Patrizia
    Sonneveld, Pieter
    Sezer, Orhan
    Vesole, David
    Cavo, Michele
    Einsele, Hermann
    Richardson, Paul G.
    Durie, Brian G. M.
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (09) : 1729 - 1735
  • [4] Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    Gertz, Morie A.
    Kumar, Shaji
    Lacy, Martha Q.
    Dispenzieri, Angela
    Dingli, David
    Hayman, Suzanne R.
    Buadi, Francis K.
    Hogan, William J.
    BLOOD, 2010, 115 (12) : 2348 - 2353
  • [5] Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy
    Lee, Sung-Eun
    Choi, Kyungmee
    Han, Seunghoon
    Lee, Jongtae
    Hong, Taegon
    Park, Gab-Jin
    Yim, Dong-Seok
    Min, Chang-Ki
    ANTI-CANCER DRUGS, 2017, 28 (06) : 660 - 668
  • [6] Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
    Mohamad Mohty
    Florent Malard
    Ali Bazarbachi
    Clinical Hematology International, 2020, 2 (2) : 92 - 93
  • [7] Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
    Rosinol, Laura
    Oriol, Albert
    Rios, Rafael
    Sureda, Anna
    Jesus Blanchard, Maria
    Teodoro Hernandez, Miguel
    Martinez-Martinez, Rafael
    Moraleda, Jose M.
    Jarque, Isidro
    Bargay, Juan
    Gironella, Mercedes
    de Arriba, Felipe
    Palomera, Luis
    Gonzalez-Montes, Yolanda
    Marti, Josep M.
    Krsnik, Isabel
    Arguinano, Jose M.
    Esther Gonzalez, Maria
    Pilar Gonzalez, Ana
    Felipe Casado, Luis
    Lopez-Anglada, Lucia
    Paiva, Bruno
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    Lahuerta, Juan-Jose
    Blade, Joan
    BLOOD, 2019, 134 (16) : 1337 - 1345
  • [8] Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
    Chakraborty, R.
    Muchtar, E.
    Kumar, S. K.
    Buadi, F. K.
    Dingli, D.
    Dispenzieri, A.
    Hayman, S. R.
    Hogan, W. J.
    Kapoor, P.
    Lacy, M. Q.
    Leung, N.
    Warsame, R.
    Kourelis, T.
    Gonsalves, W.
    Gertz, M. A.
    LEUKEMIA, 2018, 32 (03) : 712 - 718
  • [9] Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
    R Chakraborty
    E Muchtar
    S K Kumar
    F K Buadi
    D Dingli
    A Dispenzieri
    S R Hayman
    W J Hogan
    P Kapoor
    M Q Lacy
    N Leung
    R Warsame
    T Kourelis
    W Gonsalves
    M A Gertz
    Leukemia, 2018, 32 : 712 - 718
  • [10] (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials
    Wang, Anyou
    Duan, Qiaohong
    Liu, Xin
    Ding, Kaiyang
    Han, Yongsheng
    Zhu, Weibo
    Cai, Xiaoyan
    Wu, Jingsheng
    Sun, Zimin
    ANNALS OF HEMATOLOGY, 2012, 91 (11) : 1779 - 1784
12345